Get the Stockscreener App
4.85
2.02%
-0.10
After Hours:
4.81
-0.04
-0.82%
Candel Therapeutics Inc stock is traded at $4.85, with a volume of 1.33M.
It is down -2.02% in the last 24 hours and down -8.32% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$4.95
Open:
$4.9
24h Volume:
1.33M
Relative Volume:
1.34
Market Cap:
$355.25M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-2.8698
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-5.83%
1M Performance:
-8.32%
6M Performance:
-3.00%
1Y Performance:
-40.42%
1-Day Range:
$4.77
$4.985
1-Week Range:
$4.77
$5.54
52-Week Range:
$4.25
$9.08
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.85 | 362.57M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan
Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union
CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey
Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com India
Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews
Candel Therapeutics, Inc. unveils science behind CAN-2409 driving durable tumor immune response - Traders Union
Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - Bitget
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - The Manila Times
Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan
Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks
Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView
Candel Therapeutics (NASDAQ: CADL) prices $100M common stock sale - Stock Titan
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Candel Therapeutics Prices $100M Public Offering - Intellectia AI
Candel Therapeutics Faces Market Reaction Post-Secondary Offering - StocksToTrade
Candel Therapeutics’ Stock Offering Sees Market Reaction - timothysykes.com
Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI
Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Candel Therapeutics files for offering of 18.3 mln shares of common stock - marketscreener.com
Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock - TradingView
Should I hold or sell Candel Therapeutics Inc. nowJuly 2025 Action & Risk Controlled Swing Alerts - mfd.ru
Latham & Watkins Advises RTW Investments on US$100 Million Royalty Funding Agreement With Candel Therapeutics - Latham & Watkins LLP
Key facts: Candel Therapeutics secures $100M funding; plans drug launches - TradingView
Small cap wrap: EnWave, Nextech3D.ai, Candel Therapeutics, EDM Resources… - Proactive financial news
Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations - StocksToTrade
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Stock market today: Dow Jones, S&P 500 futures rise ahead of Q4 GDP numbers—Grail, Candel Therapeutics, Copart in focus - MSN
Candel Therapeutics stock falls on $100 million offering pricing By Investing.com - Investing.com Canada
Candel Therapeutics stock falls on $100 million offering pricing - Investing.com
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga
Candel Therapeutics prices $100M public offering - Proactive financial news
Akamai, Grail, Candel Therapeutics - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Is Candel Therapeutics Stock Falling Friday? - Bitget
Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus - Bitget
Candel Therapeutics Prices $100 Million Public Offering - marketscreener.com
Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Option Exercise |
1.29 |
937 |
1,209 |
53,430 |
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):